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Abstract
Evolutionary processes play a central role in the development, progression and
response to treatment of cancers. The current challenge facing researchers is to
harness evolutionary theory to further our understanding of the clinical progres-
sion of cancers. Central to this endeavour will be the development of experimen-
tal systems and approaches by which theories of cancer evolution can be
effectively tested. We argue here that the experimental evolution approach –
whereby evolution is observed in real time and which has typically employed
microorganisms – can be usefully applied to cancer. This approach allows us to
disentangle the ecological causes of natural selection, identify the genetic basis of
evolutionary changes and determine their repeatability. Cell cultures used in can-
cer research share many of the desirable traits that make microorganisms ideal
for studying evolution. As such, experimental cancer evolution is feasible and
likely to give great insight into the selective pressures driving the evolution of
clinically destructive cancer traits. We highlight three areas of evolutionary theory
with importance to cancer biology that are amenable to experimental evolution:
drug resistance, social evolution and resource competition. Understanding the
diversity, persistence and evolution of cancers is vital for treatment and drug
development, and an experimental evolution approach could provide strategic
directions and focus for future research.
Introduction
Recently, there has been a shift in current thinking among
cancer researchers that acknowledges the importance of
evolution in understanding cancer progression within a
host. This movement has been guided by an increasing
body of seminal work (e.g. Vogelstein and Kinzler 1993;
Leroi et al. 2003; Merlo et al. 2006; Attolini and Michor
2009; Sequist et al. 2011; Gerlinger et al. 2012; Greaves and
Maley 2012) reinvigorating old ideas (Nowell 1976) regard-
ing the evolution and ecology of cancers. Recent studies
have detected rapid evolution and spatially structured
genotypic and phenotypic diversity both within tumours
and between primary and secondary tumours (Frumkin
et al. 2008; Stoecklein et al. 2008; Sequist et al. 2011;
Gerlinger et al. 2012). The consideration of evolutionary
progression of cancers is therefore not just desirable it is
essential. Cells become cancerous when mutations arise
which increase their replication rate and survival advantage
compared with neighbouring cells; subsequently, natural
selection will act on these cells and ultimately ensure the
proliferation of the mutant lineage (for reviews, see Crespi
and Summers 2005; Merlo et al. 2006; Greaves and Maley
2012). Once cancerous traits have evolved, an elevated
mutation rate and metastatic potential may facilitate diver-
sification and persistence of the cancerous cells (Bielas
et al. 2006). Moreover, aggressive drug treatment of can-
cers will unavoidably select for resistant lineages, which
become increasingly difficult to treat. However, by under-
standing how the environment shapes the evolution of can-
cerous traits, we can begin to anticipate evolutionary
trajectories and apply a more proactive treatment strategy
(Cairns 1975; Aktipis et al. 2012; Yap et al. 2012).
There are a number of factors that will determine the fit-
ness of cancerous cells within a host. The immediate micro-
environment will present challenges for space and
resources, and the extended microenvironment will pro-
vide further challenges in the form of vascularization and
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the realization of metastatic potential (that is the migration
and colonization of cancer cells to secondary sites within
the host). Although substantial effort has been conducted
into understanding mechanistic consequences of cell–cell
and cell–environment interactions, the evolutionary and
ecological outcomes have not been explicitly tested. These
have left fundamental questions regarding cancerous
behaviours unanswered, such as: How do competitive
interactions between cells determine disease progression?
What are the fitness costs of drug resistance? How do the
selective pressures between different environments effect
disease progression (e.g. liquid versus solid cancers)?
Answering these and other pressing questions in cancer
biology will require carefully designed experiments that
explicitly test competing evolutionary hypotheses of cancer
progression, which are led by observational data from clini-
cians highlighting the medically important traits.
In this article, we propose that to answer some of the
fundamental questions regarding the evolutionary progres-
sion of cancers, cancer biologists should adopt the powerful
techniques of experimental evolution. Seminal experimen-
tal evolution studies have fundamentally changed our
understanding of evolution in terms of adaptation (Lenski
et al. 1991), diversification (Rainey and Travisano 1998),
social evolution (Turner and Chao 1999; Velicer et al.
2000), evolutionary trade-offs and constraints (Novak et al.
2006; Blount et al. 2008), repeatability (Lenski et al. 1991;
Lenski and Travisano 1994; Cooper et al. 2003; Woods
et al. 2006; Barrick et al. 2009) and more besides; there is
strong potential for similar advancements in cancer biol-
ogy. Experimental evolution uses replicate populations of
organisms with fast generation times (typically microor-
ganisms) to study evolutionary processes in real time (for
review see, Elena and Lenski 2003). The experimenter con-
trols the environmental conditions under which evolution
occurs and monitors the effect of specific selective pressures
on traits of interest (Buckling et al. 2009). One major bene-
fit of this system is that evolved and ancestral lines, or mul-
tiple evolved lines, can be competed against each other to
measure fitness under defined ecological conditions, and
the accumulation of mutations can be followed in a rigor-
ously defined and time-directional manner over numerous
generations.
Cancer cells can conveniently be grown in vitro, and
these cancerous tissue cultures share many beneficial char-
acteristics with microbial model systems used for experi-
mental evolution studies (Table 1). A promising new area
of research therefore suggests itself: experimental cancer
evolution, which could provide new insights into disease
progression and aid the strategic development of new drug
therapies and treatment regimes.
Here, we discuss three general evolutionary problems
that have the potential to dramatically influence the evolu-
tion of cancerous traits, but remain to be rigorously
explored empirically: the evolution of drug resistance and
associated costs, cooperation and conflict between cancer-
ous and noncancerous cells, and resource competition as a
driver for the evolution of metastasis. Although all three
have already been successfully addressed using experimen-
tal evolution in microbes, cancers provide a new challenge
to understand how predictions derived from simpler bio-
logical systems translate to a more complex one. Cancers
have a comparably larger molecular ‘tool kit’ and a com-
plex relationship within the ‘cell community’. Noncancer-
ous cells are programmed for a multicellular lifestyle and
will thus act altruistically for the benefit of the host, but
Table 1. Features of microorganisms which make them an ideal model system for studying evolution experimentally (Elena and Lenski 2003) and
parallels in cancer cells.
Microorganisms Cancer cells Advantages for evolutionary experiments
Easy to propagate and enumerate Immortal lines can be easily grown, and lines
which have been used extensively in research
for decades are well enumerated
Cells can be grown at low cost and in high volumes.
Prior details of normal behaviour allow interesting
mutants to be identified
Fast replication Generation time of approximately 1 day Allows experiments to conceivably run for many
generations
Manipulable mutation rates Elevated mutation rate compared to
noncancerous cells
Facilitates variation by mutation within the population
Large populations exist in small spaces Billions of cells can be grown in tissue culture
flasks
Aids experimental replication
Stored easily and indefinitely in suspended
animation
Cells can easily be frozen and revived Enables comparisons between ancestral and evolved
lineages; lineages can be catalogued and revived
Asexual reproduction Cells divide mitotically Clonality assists experimental replication
Easily manipulated experimental conditions
and genetic composition of founding
populations
Culture resources and environment are easily
controlled
Allows identification of environmental and genetic
influences on evolutionary processes; advancements
in sequencing means genetic identification is easier
and more cost-effective than ever before
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cancer cells (which share the same signalling pathways)
have the ability to manipulate these altruistic cells for selfish
objectives. These factors have the potential to alter standard
predictions made from unicellular models, but importantly
will help to identify major issues which are likely to be key
in the context of disease progression. To account for these
differences between microbes and cancers (thus resulting in
more accurate predictions regarding evolutionary trajec-
tory), experimental evolution studies need to be conducted
which explicitly test evolutionary theory within the context
of cancer. A glossary is provided for definitions which
might not be familiar to both fields (Box 1).
Costs of resistance and trade-offs
The evolution of drug resistance is a process of adaptation
by natural selection and has been well described by popula-
tion genetics models (reviewed in, Levin et al. 2000; but see
also Read and Huijben 2009). In particular, the relationship
between mutation rate and the fitness effects of mutations
is key. Genetic instability is a trait which is considered a
hallmark behaviour (Hanahan and Weinberg 2011) of can-
cer. A high mutation rate is usually associated with a fitness
cost, because most mutations are deleterious. However, a
heterogeneous and frequently changing environment pro-
vides selection for phenotypes with elevated mutation rates,
because increased genetic variation allows faster adaptation
(Sniegowski et al. 1997). An accurate estimate of mutation
rates of cancerous cells in vivo is yet to be determined; how-
ever, this information is key if we hope to better understand
the predictability of resistance evolution. In particular, a
newly developed approach by Wielgoss et al. (2011) uses
whole genome sequencing combined with experimental
evolution to provide a highly accurate measure of bacterial
base-substitution rates – by sequencing several E. coli ge-
nomes after a 40 000 generation evolution experiment, they
were able to directly infer the point mutation rate based
accumulation of synonymous mutations. A similar
approach could be adopted using cancer cells to try and
identify why different cancers appear to vary in their muta-
tion rate, and what impact mutagenic chemotherapy drugs
have on baseline mutation rates (Loeb 2001).
Fitness effects of mutations are also crucial in determin-
ing their fate: resistance mutations are generally associated
with a reduced fitness in the absence of the drug – this
trade-off is termed the cost of resistance. Costs occur
because resistance is typically achieved through alteration
of the trait(s) targeted by the drug leading to impaired or
lost function. If resistant lines carry a fitness cost but are
still allowed to evolve in the presence of the drug, natural
selection will act to counterbalance the cost while preserv-
ing the resistance, and as such resistant mutants will
acquire new mutations which compensate for the fitness
decline. These compensatory mutations are important in
determining the probability of loss of resistance in a drug-
free environment, because the fitness of mutants which
have fixed compensatory mutations is conditional on the
presence of the resistant mutations for which they compen-
sate, thus in the absence of the resistance mutation, the
compensatory mutations may carry a fitness cost, therefore
reducing the likelihood of reversion (Schrag et al. 1997;
Maisnier-Patin and Andersson 2004).
Recent studies have seen rapid evolution of drug resis-
tance in cancers which occur due to mutations in the epi-
dermal growth factor receptors (EGFR), including non-
small-cell lung cancer (NSCLC) and colorectal cancers
(Kobayashi et al. 2005; Turke et al. 2010; Sequist et al.
2011; Diaz et al. 2012). EGFRs are essential for cell growth
and development, and highly conserved across all animals
(Bogdan and Kl€ambt 2001); for this reason, they are a com-
mon target site for cancer drugs, because by blocking the
EGFRs, it is possible to slow cell growth. Sequist et al.
(2011) found patients whose NSCLC had been treated with
an EGFR blocker (tyrosine kinase inhibitor; TKI) evolved
resistance within 12 months. To investigate the mechanism
of resistance, genetic and histological testing was carried
out on 37 patients with NSCLC treated with TKIs. It was
discovered that all 37 samples had acquired new mutations
related to the disruption of EGFR function, in addition to
the original EGFR mutations which had triggered cancer-
ous behaviour. This study clearly demonstrates that cancer
cells which modified their EGFRs to disrupt binding of
TKIs acquired resistance. However, changes to these recep-
tors are likely to have large negative fitness effects on the
cell, because they will be associated with less efficient cell
growth, but the actual costs of these fitness effects remain
to be explicitly measured. Competition experiments (Fig-
ure 1) could be used to quantify these costs and as such,
improve the predictive power of the evolution of resistance
to drugs which target EGFRs. Competition experiments
involve directly competing ancestral and evolved (i.e. sus-
ceptible and resistant) populations of cells in order to esti-
mate the relative fitness of each cell type. The likely large
costs associated with changes to the EGFR are further
exemplified in this study, because after some patients with
resistant cancers stopped treatment with TKIs, the resis-
tance mutations were lost, and their tumours once again
became sensitive to treatment by either the same or a dif-
ferent EGFR inhibitor. Reversion may occur if the cost of
the mutation conferring resistance is very high, but is unli-
kely if compensatory mutations have negated this cost.
Therefore, in this specific study, the cost of resistance
appears to be very high, and the effect of compensatory
mutations, low – a promising observation in terms of man-
aging drug resistance, and a measurable effect with in vitro
testing.
© 2012 The Authors. Published by Blackwell Publishing Ltd 3
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Similarly, rapid evolved resistance to TKIs is seen in
chronic myeloid leukaemia (CML) (Blagosklonny 2002;
Shannon 2002; Shah et al. 2007). Resistance is acquired via
point mutations to BCR-ABL (a gene responsible for con-
stitutive tyrosine kinase activity) that cause structural
changes which perturb binding of the drug (Gorre et al.
2001). Population genetics have been applied to clinical
data to try and gain an insight into how TKIs exert its ther-
apeutic effect in CML (Michor et al. 2005), finding that
TKIs dramatically reduces the rate at which cancer progeni-
tors are produced from the stem cells, but does not lead to
a decline of stem cells themselves. In addition, they found
the probability of evolving resistance increased with disease
progression, as a consequence of increased stem cell abun-
dance. This combined molecular and mathematical
approach shows promising and informative direction for
future development.
When resistance occurs, multiple drugs are commonly
administered in the hope that bombarding the cells will
mean full resistance is impossible (or at least improbable).
However, the success of such an approach requires a
detailed understanding of drug interactions: antagonistic
interactions between drugs (i.e. drugs which inhibit each
other’s effects) will most likely lead to a low rate of evolu-
tion of multidrug resistance, because a mutation that con-
fers resistance to one drug will be associated with only a
marginal benefit; however, when interactions between
drugs are synergistic (i.e. enhance each other’s effects),
resistance mutations will be associated with large benefits,
and rapid multidrug resistance is expected (Hegreness et al.
2008; MacLean et al. 2010). There has been much research
showing the importance of the microenvironment in deter-
mining cancer behaviour, and it is likely to be central in the
context of evolution of drug resistance. By administering
different drug strategies in the lab, which are known to be
antagonistic or synergistic in their actions, under different
environmental conditions (such as nutrient content, tissue
type or genetic variability of tumour mass) we can test pre-
(A)
(B)
Figure 1 The simple competition experiment is one of the most powerful tools in experimental evolution. It allows ancestral and evolved populations
to be directly competed to provide an estimate of relative fitness between populations under defined ecological conditions. Ancestral and evolved
populations are grown separately, and then mixed at a 1:1 frequency. They are allowed to grow and compete, after which the frequency of each
population is estimated by plating a subset of cells onto a hard media and counting each colony type (cells may need to be tagged to allow differenti-
ation). After Elena and Lenski (2003) and Buckling et al. (2009).
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dictions regarding the evolution of drug resistance and gain
a greater understanding as to what extent evolutionary tra-
jectories are predictable.
In microbes, there has been a drive to understand the
evolution of resistance due to the misuse of antibiotics
leading to widespread antibiotic resistance. As such many
techniques have been developed which measure the key
components of the evolution of resistance, such as muta-
tion rates, costs of resistance, compensatory evolution,
multidrug resistance, and selection gradients. For instance,
costs of resistance have been accurately measured using
competition experiments (Figure 1) whereby the ancestral
strain (which is susceptible to the antibiotic) and the resis-
tant strain are grown together in the absence of the antibi-
otic. A subset of the population is then plated onto agar
plates to allow growth of each strain type to be determined.
Comparing the ratio of ancestral and resistant colonies
enables fitness estimates to be made. This information
allows one to determine the effect of antibiotic use under
ideal conditions for microbial growth and predict conse-
quences for in vivo use, enabling calculated risk assessment
in antibiotic treatment. These experiments are all quick
and simple to conduct and cheap to run – and similar
experiments could be conducted using a cancer system.
In addition, a theoretical approach using adaptive walks
allows predictions to be made regarding the likelihood of
reversion of a resistance mutation to its susceptible ances-
tral genotype given a certain selection gradient and fitness
landscape. Microbial data suggest that compensatory muta-
tions are more likely than reversions, because there are sev-
eral possible compensatory mutations for each resistance
mutation (Poon et al. 2005). Moreover, compensatory
mutations may be harmful in the absence of the original
resistance mutation, further decreasing the chance of rever-
sion (Schrag et al. 1997; Maisnier-Patin and Andersson
2004; Andersson 2006). Current research suggests that
microbes cannot be relied on to lose resistance to an antibi-
otic if its use is discontinued (Andersson 2006; although
see, Andersson and Hughes 2010), and therefore, we might
predict that the rate of cancer cells losing resistance will
depend on the type of drug used, the strength of selection
and the degree of competition within the tissue (Komarova
and Wodarz 2005; Szakacs et al. 2006). However, evidence
from cancer research seems more promising. Several rever-
sions to susceptible phenotypes were observed in one study
(Sequist et al. 2011): but, how can we account for these
apparent differences?
We suggest that this difference is due to disparities in
drug action. Antibiotics can rapidly kill bacteria without
destroying human cells because they exploit the differences
between bacterial and eukaryotic cells. The differences
between cancerous and healthy human cells are, by con-
trast, subtle, involving quantitative differences in gene
expression (Zhang et al. 1997). Cancer treatment is there-
fore a more sensitive compromise between efficacy and
toxic side effects, involving longer courses of treatment,
typically several months. This means selection for drug
resistance in cancer cells is weaker, but more prolonged,
than selection for antibiotic resistance; mutations confer-
ring resistance will be favoured, but any pleiotropic delete-
rious effects on fitness must be minimal. When bacteria are
challenged with an antibiotic, however, selection pressures
are strong, so mutations conferring resistance can fix even
if they have considerably deleterious pleiotropic effects.
Potential compensatory mutations are therefore more
advantageous, and fix more rapidly. This hypothesis is test-
able using microbes and cancer cell lines.
Social evolution: conflict and cooperation
The social environment – the behaviour of an organism’s
neighbours – can have a direct impact on fitness. These
interactions are often thought of as negative: for instance,
individuals that are competing for scarce resources will
reduce each other’s fitness. However, social interactions
can also provide benefits if, for example, mutually secreted
enzymes free up nutrients for neighbouring cells (Lee and
Schneewind 2001; Nadell et al. 2010). Under these circum-
stances, the behaviour can be considered cooperative
because the action benefits both the actor and the recipient
(West et al. 2007). Cooperation can be split into two sub-
groups: mutualism, whereby both individuals contribute to
a behaviour to which both gain benefit; and altruism,
whereby an action benefits the recipient but comes at a cost
to the actor. Altruism in particular posed a problem for
evolutionary biology: how can a behaviour evolve which
appears costly to the individual but beneficial to others
(Maynard Smith and Szathmary 1995; Hamilton 1996)?
Hamilton (1964) explained the evolution and maintenance
of altruistic behaviours through relatedness, whereby coop-
erative interactions can evolve if the benefit from such an
interaction is most likely received by a kin member. This is
because improving the fitness of a kin member helps to
propagate the shared genes between the helper and the
helped – thus an indirect benefit is gained. Mutual benefit
cooperation on the other hand provides a direct benefit to
all contributors, and therefore can evolve in the absence of
high relatedness.
The evolution of multicellularity is considered one of the
major evolutionary transitions in the history of life on earth
(Maynard Smith and Szathmary 1995). For multicellularity
to evolve, cells are required to transition from unicellular
individuals acting selfishly to proliferate their own survival,
to being part of a group where survival is maximized
between many cooperating individuals. For this to occur,
competition between selfish entities must be repressed, and
© 2012 The Authors. Published by Blackwell Publishing Ltd 5
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individual cell fitness aligned with group cell fitness (Leigh
1977), otherwise there will be a selective drive to defect
from a multicellular lifestyle in favour of a solitary one
(Frank 2003; K€ummerli et al. 2010). In our own bodies,
individual somatic cells cooperate to maximize lifetime
reproductive success, and thus transmission of the genes
which are shared by every cell in our body. Cancer cells
undergo this major transition in reverse, and abandon a
cooperative existence to selfishly outgrow normal cells. At
this point, the focused level of selection (in terms of under-
standing disease progression) shifts from the group to the
individual cell (Klein 2003; Gardner and Grafen 2009).
However, this transition poses some interesting ques-
tions as to how these rogue cells interact with their social
environment given that they possess the machinery to
manipulate their competitors. Cell–cell interactions are
vital in disease progression, resulting in complex hetero-
typic interactions where tumour cells interact with each
other in addition to the normal stromal cells within the tis-
sue microenvironment and vice versa (Weaver and Gilbert
2004; Axelrod et al. 2006). Noncancerous cells use signal-
ling networks and mutually secreted enzymes in normal cell
growth; however, cancer cells use these same pathways and
signals for abnormal cell growth. Cancer cells are known to
interact with each other and with cells from the tumour
microenvironment – recruiting noncancerous cells to facili-
tate proliferation (Hanahan and Coussens 2012), and
recent research has noted the conceptual similarities
between cancer and bacteria in terms of social behaviours
(for review see Ben-Jacob et al. 2012). There is evidence
that certain hallmark behaviours (Hanahan and Weinberg
2011) of cancer cells require the excretion of products
(sharable resources) which will be beneficial to other cancer
cells within the vicinity (Stetler-Stevenson et al. 1993;
Coussens et al. 2002; Egeblad and Werb 2002): this is coop-
erative behaviour. Cooperative behaviours are intrinsically
involved in several steps of tumour progression, such as
angiogenesis, self-sufficiency in growth signals and tissue
invasion (Table 2). This leads to a scenario of both cooper-
ation and conflict, whereby cancer cells are regarded as
cooperators in terms of the disease, but create conflict (i.e.
behave as cheats) in the eyes of the host.
The tensions between cooperation and conflict over
shared resources has been extensively researched in micro-
bial systems, and some seminal papers have fundamentally
changed our view of the social world microbes live in
(Chao and Levin 1981; Turner and Chao 1999; Strassman
et al. 2000; Velicer et al. 2000; Queller et al. 2003; Fiegna
et al. 2006). Bacteria produce numerous extracellular mole-
cules, such as tissue degrading enzymes, iron-scavenging
siderophores and sticky polymers to protect surface grow-
ing bacteria (biofilms), which are individually costly but
benefit the group as a whole (West et al. 2007). Using tech-
niques from experimental evolution on microbial systems
Table 2. Examples of ‘mass action cooperation’ (Heckathorn 1996) in cancers, where mutualisms form between different clones and cells within the
microenvironment
Behaviour Cooperative characteristics
Angiogenesis Tumours require nutrients and oxygen to grow. Therefore, they must recruit new blood vessels into the area
(neoangiogenesis) by secreting vascular endothelial growth factor (VEGF). The recruitment of blood vessels
to an area not only benefits the secreting cells but also any cells within the local vicinity. Therefore, VEGF
can be thought of as a communal product, the production of which is likely to carry an energetic cost to the
producer, and a growth benefit to any recipients. Evidence for this behaviour has already been shown in cancer–
stromal–cell interactions, and there is growing evidence that it may also be important between cancer cells
(Kalas et al. 2005).
Self-sufficiency in growth signals Cancer cells produce many growth factors (such as VEGF, PDGF and TGF-b) (Mueller and Fusenig 2004)
that induce stromal reactions for angiogenesis and inflammation, and activate other stromal cells, such as
fibroblasts, to secrete other growth factors (GFs) and proteases (de Jong et al. 1998; Klein 2003; Weaver
and Gilbert 2004). Although not systematically tested, there is some evidence that cancer cells secreting GFs
are frequently adjacent to cells which express GF receptors, and therefore have the potential to respond to GF
signals (de Jong et al. 1998; Royuela et al. 2004). This suggests that cancer cells are able to share GFs
between each other, and also recruit GFs from noncancerous cells, which will aid tumour growth.
Tissue invasion Cancer cells interact with stromal cells to stabilize the tumour microenvironment. Normally, tissue cells remain
confined to their territory because they respond to signals from neighbouring cells, and the extra cellular
matrix (ECM). Any cells which become detached receive apoptotic signals from the invaded tissues, and as such
are eliminated. Malignant tumour cells effectively ignore these signals, and so are able to migrate beyond the
defined boundaries of the tissue (Liotta and Kohn 2001). Stromelysin-3 secreted by fibroblasts peripheral to the
tumour is known to reduce the death rate of cancer cells invading adjacent connective tissues. In addition,
proteases from nearby stromal and cancer cells are known to contribute to neoplastic progression by degrading
ECM, aiding in cell proliferation, tissue invasion and metastasis (Tlsty 2001).
© 2012 The Authors. Published by Blackwell Publishing Ltd6
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has enabled us to explore theories regarding the evolution
of cooperative behaviours, and gain a better understanding
for how they might be maintained within a population.
Evidence suggests cooperation will be maintained
through indirect and direct fitness benefits (Griffin and
West 2002). Indirect fitness benefits require high related-
ness within the population, ensuring cooperative behav-
iours benefit local kin members. Direct fitness benefits can
occur if individuals have a shared selfish interest in cooper-
ating, for example, in the case of cross-feeding (where the
waste product of one species is an energy source for
another; Bull and Harcombe 2009). Moreover, it has been
successfully established, using microbes, that social behav-
iours often involve frequency-dependent selection (Queller
1984). This is because a ‘cheating behaviour’, that is letting
those around you contribute to a public good so you don’t
have to, is only a successful strategy if it is rare. This is
likely to be important in the context of cancers because
these factors will limit the size at which tumours can suc-
cessfully function. The influence of such factors is easily
addressed using competition assays (Figure 1) which vary
in the initial frequencies of altruists and cheats (Ross-Gil-
lespie et al. 2007).
Bringing social evolution research into the context of
cancer will give new insights into the levels of selection and
transitions to multicellularity. The experiments can start
simple: spheroids (artificial masses of cancer cells), which
are made up from cells of varying genetic diversity, are
exposed to a range of environments which alter the com-
petitiveness between cells (e.g. varying nutrient condi-
tions). Here, we can look to see whether the predictions
made by social evolution theory are fulfilled, and build on
this knowledge with more complex experiments. Due to
the easy manipulation of spheroid diversity, it gives the
potential for cancer to make an elegant system on which
some important questions can be answered: How does
relatedness influence relative competition between cells? Is
competition beneficial (because it encourages cooperative
behaviours and metastasis) or disadvantageous (because
cells have less individual resources) for tumour growth?
Resource competition: dispersal and metastasis
Metastasis in cancer is conceptually equivalent to dispersal
in ecology. As disease progresses, cells detach from the pri-
mary tumour and circulate in the bloodstream, where some
go on to colonize new tissues and establish metastatic
tumours (Friedl and Wolf 2003). Likewise, dispersal is the
relocation of individuals from a natal site, a behaviour
which provides the opportunity for population expansion
via colonization events. It is therefore essential to apply the
well-established evolutionary theories of dispersal to under-
stand metastasis.
Dispersal is a risky strategy: a dispersing individual may
die, settle in an unsuitable habitat or find itself in competi-
tion with locally adapted rivals, and for many organisms,
the probability that dispersal will pay off is extremely low.
Yet dispersal is ubiquitous across the spectrum of life: from
microbes, to plants, to birds. To understand how dispersal
strategies evolve, one must understand the costs and bene-
fits which will determine when and how dispersal is
favoured, and the ecological subtleties which shape the
behaviour. Fundamentally, the benefit of dispersal is that it
allows an individual to escape local competition (providing
an indirect fitness benefit) and gain access to resources
(providing a direct fitness benefit) (Bowler and Benton
2005; Wei et al. 2011). A crucial breakthrough was the rec-
ognition that dispersal is often a social trait such that
organisms might pay high costs for dispersal if they are sur-
rounded by kin. When individuals within the population
are genetically similar (termed related), the overall benefit
of dispersal is maintained, even when individual costs of
dispersing are high (Hamilton and May 1977; Comins et al.
1980; Taylor and Frank 1996; Gandon and Michalakis
1999; Taylor and Buckling 2010). This is because the inclu-
sive fitness of an individual is determined not only by how
many genes it directly passes onto the next generation but
also by how many genes shared with related individuals are
also passed on (termed indirect fitness). This social consid-
eration in terms of dispersal supports the paradoxical
observation of how dispersal might evolve even when most
dispersing individuals themselves die: a dispersing individ-
ual can increase the chances that related individuals, who
forego dispersal to compete for resources, will benefit from
decreased competition and consequently the disperser will
benefit indirectly.
Limited dispersal will increase relatedness (favouring the
evolution of altruistic traits), but increase local competition
among relatives (disfavouring altruism). Theoretically, in
the simplest scenario, these two factors exactly cancel each
other out, such that the level of dispersal has no effect of
the evolution of altruism (Taylor 1992). However, the con-
sideration of more complex scenarios provides mechanisms
for ways in which limited dispersal can still favour altruism
(Lehmann and Keller 2006; Alizon and Taylor 2008). One
such mechanism which can provide a solution to the main-
tenance of social traits with dispersal is the process of bud-
ding dispersal. Experimental evolution has shown that this
trade-off between limited dispersal and increased local
competition can be circumvented when cooperators dis-
perse in small aggregated groups (K€ummerli et al. 2009),
thus keeping relatedness high and allowing the colonization
of new patches where competition is low. There is evidence
that cancer cells do not only migrate individually, but also
collectively, in a behaviour comparative to budding dis-
persal (Friedl and Wolf 2003). This behaviour increases
© 2012 The Authors. Published by Blackwell Publishing Ltd 7
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tumour invasion efficiency and survival probability
through the maintenance of social behaviours, for example:
the larger cell mass maintains high endocrine concentra-
tions, protects inner cells from risks encountered during
dispersal, and also promotes invasion of cells which are less
mobile. It is yet to be determined how common metastatic
secondary tumours are established via collective-cell move-
ment, but evolutionary theory would predict that the dis-
ruption of group migration would decrease metastatic
formation under this scenario.
One theoretical finding of particular relevance is that
population processes and the evolution of dispersal are
highly interdependent. Specifically, demographic features
of the population will determine dispersal rate, and dis-
persal rate will alter population demography (Ronce 2007).
To understand the maintenance and stability of dispersal
strategies, it is vital to consider feedbacks between evolu-
tionary and ecological processes associated with dispersal.
In cancers, for example, the increasing cell density in a
growing tumour will alter the local environment (especially
the intratumour microenvironment), rapidly reducing
nutrient levels and oxygen availability; this, in turn, will
feedback into the population demography – increasing rel-
ative competition between cells for a dwindling pool of
resources. This competition may change relative selective
pressures: decreasing the benefit gained from associating
with nearby cells, and increasing the benefit of dispersing,
which will provide the opportunity to escape competition
and potentially colonize new empty patches.
Metastatic cancers are the most aggressive and have the
poorest outcomes in terms of patient survival (Liotta et al.
1991). However, only a vanishingly small proportion of
metastatic cells establish a new tumour (Butler et al. 2000),
and metastatic cells are at a significant disadvantage in
competition for space and resources (Chen et al. 2011).
The problem of explaining how metastasis evolves despite
high apparent costs was identified by Bernards and Wein-
berg (2002): ‘(T)here is no reason to think that a metastatic
phenotype enables cells to proliferate more effectively
within the primary representation in the overall tumour-
cell population’. In other words, metastasis should only
exist as a rare trait, overwhelmingly dominated by static
phenotypes which do not pay the cost of dispersal. Unfor-
tunately, this does not describe the observed patterns of
metastatic progression (Liotta and Kohn 2003), with an
estimated 106–107 cells emigrating daily from a developed
neoplasm (Butler et al. 2000).
Dispersal ecology theory was recently applied to this
problem, and metabolic rate, determined by resource heter-
ogeneity within primary tumours, was considered a selec-
tive agent for high cell motility (Anderson et al. 2006;
Chen et al. 2011; Aktipis et al. 2012). The microenviron-
ment surrounding a growing neoplasm can quickly change
over small distances, becoming hypoxic (Harris 2002; Brur-
berg et al. 2003, 2005; Vaupel and Harrison 2004; Carde-
nas-Navia et al. 2008) due to poorly regulated
angiogenesis, changes in vascular architecture, or tempo-
rary obstruction or interruption of blood flow by neoplas-
tic cells (Boucher and Jain 1992; Araujo and McElwain
2004; Vaupel and Harrison 2004). The effect of spatial and
temporal resource availability was modelled mathemati-
cally with the conclusion that resource heterogeneity selects
for cell motility, and cell dispersal is an evolutionary conse-
quence of that selection (Chen et al. 2011).
Insights from experimental evolution using microbial
model systems show that kin competition can indeed drive
the evolution of dispersal behaviour. Taylor and Buckling
(2010) found that the benefit of dispersal was much higher
in clonal (highly related, or kin based) bacterial popula-
tions, and these clonal populations were more likely to dis-
perse under very high resource-dependent costs than
mixed dispersal strategy populations. In addition, Wei
et al. (2011) found bacterial motility provided large bene-
fits to a bacterial population by allowing individuals to
move away from each other and thereby obtain a greater
share of resources in physically structured environments.
These types of studies provide a framework to develop sim-
ilar experiments in a cancer cell system (Box 2), which will
provide vital data on basic questions concerning metastatic
behaviour, for example: Is metastasis a heritable trait? To
what extent does environment determine metastatic behav-
iour over genetics? and What role does the cost of dispersal
play in determining the success of new tissue invasion, and
how does the social environment alter these costs?
Crucially, cancer cells do differ from microbes, and their
own natural history must be considered. Even including
transmission in utero, there are extremely few known
instances in which a human cancer has dispersed outside
its original host, and no known outbreaks of repeated host-
to-host transmission (Dingli and Nowak 2006). Of the
three transmissible tumours known from other mammals,
only canine transmissible venereal tumour (CTVT) has
spread through a typical host population. Devil facial
tumour disease (DFTD) infects Tasmanian devils, a criti-
cally endangered species with low genetic diversity, and
transmissible hamster sarcoma spread via a vector through
laboratory animals which shared sufficient genetic identity
(Banfield et al. 1965).
We posit that in the long run, a cancerous cell line is
doomed, because they have not evolved a long-term strat-
egy to promote vertical or horizontal transmission. Of
course, evolution has no foresight, so this ultimate futility
does not in itself affect the progress of disease. However,
selection for colonization ability can only occur at coloni-
zation events; even where selection is very strong, it must
also be iterative to build up complex adaptations. Cancers
© 2012 The Authors. Published by Blackwell Publishing Ltd8
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undergo relatively few colonization/dispersal cycles, and
consequently cannot build up the intricate adaptations for
dispersal and establishment found in independent organ-
isms; instead, they may crudely redeploy existing motility
pathways, such as those used in development and wound
healing. This may result in maladaptive or suboptimal
behaviours that could be exploited in cancer treatment.
Concluding remarks
In this article we have discussed how methods from
experimental evolution can be applied to help understand
the evolution of cancers. Considering cancers from an
ecological and evolutionary perspective should lead to
innovative approaches to disease control and drug treat-
ment. There are many lessons to be learnt from evolu-
tionary theory, and a cancer tissue model system shares
many of the advantages of a microbial model system,
providing great potential for addressing evolutionary
questions regarding disease progression in a biologically
relevant system. In cancers, this model system has the
advantage of direct applicability to the disease model. In
particular, understanding the repeatability of evolutionary
processes would have significant clinical applications for
cancer biology, as currently, cancer types are often treated
as distinct from each other, requiring independent ave-
nues of research in order to understand their differences.
However, by focusing on the similarities between cancers
rather than the differences, universal treatment strategies
may be identified.
We must, however, consider the limitations of experi-
mental evolution and despite its proven success in micro-
bial models – the methods have also received criticism
(Buckling et al. 2009), namely concerning its realism to
more natural settings. The laboratory is not a natural envi-
ronment, and therefore some argue the results are not
applicable to the ‘real-world’. However, during the course
of an experimental study, an organism will adapt to its lab-
oratory environment (in fact, many commonly used cancer
cell lineages have been maintained in laboratory conditions
already for many generations). Therefore, these organisms
will be adapted to the environment in which they are
assayed – the alternative is to take organisms out of the
environment to which they are adapted and measure them
under laboratory conditions. This will likely mask the
effects of the selective agent being considered, as expression
of the trait of interest may be modified by unfamiliar sur-
roundings. Furthermore, the approach has been criticized
for being too simplistic in comparison to real-world com-
plexity. However, the simplicity of design is the exact bene-
fit of this method – using a simple model system captures
the influence of certain identified selective factors on a trait
of interest – thus improving overall generality of the
results.
Identifying mechanisms that directly influence the evolu-
tionary progression of a disease requires in depth under-
standing of the genetic, behavioural and physiological
components within a phenotypic context. The first step in
this process is the development of evolutionary theory in a
mathematical model to identify and quantify the selective
factors which determine evolutionary processes. Evolution-
ary models are now being used to explore the evolutionary
progression of cancers, and opening the door for commu-
nication between disciplines in the process (Nunney 2003;
Anderson et al. 2006; Chen et al. 2011). However, without
empirical synergy, the true applicability of these models is
difficult to determine. Empirical systems bridge the gap
from theory to clinical reality, which enables the translation
of ideas and evolutionary risk analysis of drug treatment
and disease progression.
The three examples of relevant evolutionary questions
discussed above are by no means an exhaustive list. The
first step for these experimental evolution studies should be
to identify the population dynamics which will influence
evolutionary processes, such as measurement of mutation
rates, fitness effects of mutations, generation times, popula-
tion structure, the frequency of selective sweeps and the
selective effects of drug therapies (Merlo et al. 2006). The
second step should be to identify the ecological effects dif-
ferent environmental conditions have on such processes.
The third step should be to identify the genetic mecha-
nisms underlying the evolution of disease-related behavio-
ural changes. Finally, we should be able to apply such
knowledge to patient-specific cases, with the hope of pre-
empting progression of the disease with personalized treat-
ment strategies.
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Box 1: Glossary
Adaptive walks Sequences of beneficial mutations
Altruistic An action directed towards another individual which results in a cost to the helper and a benefit to the helped
Angiogenesis The physiological recruit of new blood vessels
Compensatory mutations Mutations which offset the negative fitness effects imposed by another mutation
Cooperative An action which benefits both the helper and any helped
Demographic features Characteristic features of a population
Direct fitness An individual’s own genetic contribution to the next generation
Epidermal growth factor receptors Surface growth factor receptors
Fitness landscape A multidimensional space where an artificial landscape comprised peaks and valleys represents a genotype or
phenotype fitness value
Hallmark behaviours Common traits of cancer cells
Hypoxic Oxygen depleted environment
Inclusive fitness The sum of an individual’s direct and indirect fitness
Indirect fitness The genetic contribution to the next generation gained from the reproduction of relatives
Kin member Genetically related individual
Metastatic (metastasis) Secondary tumours caused by the migration of cells from the primary tumour to other tissues within the body
Mutualism Ecological relationship beneficial to both partners
Neoplasm An abnormal tissue mass
Phenotype Observable characteristics of an individual resulting from the interaction of its genotype with the environment
Reversion Back mutation of a point mutation to its ancestral state
Relatedness The level of consanguinity between two given individuals
Selection gradient The slope of a regression of fitness on trait value
Somatic cells Cells which make up the tissues of the body (i.e. not the germ cells)
Stromal The supporting tissue of an organ
Tyrosine kinase inhibitor (TKI) A drug that interferes with cell communication and growth and may prevent tumour growth
Box 2: A Thought Experiment
Using in vitro techniques to understand how resource competition between cells can drive metastasis in cancers – an experimental evo-
lution approach
Metastasis – the progressive spread of malignant cells away from its origin to colonise new tissues – is the most deadly aspect of can-
cer, and therefore, understanding the processes which encourage cell movement is of integral interest to the field. From the cancer’s
perspective, metastasis offers the opportunity to escape deteriorated patches and colonise unexploited, healthy tissue. Dispersal theory
has been applied to cancer research, giving evolutionary explanations for trends in cell motility via a Darwinian fitness approach. Such
theory predicts that increased competition between cells, via factors such as resource depletion, should promote dispersal and thus
encourage metastasis.
Prediction:More motile cells will be fitter when competition between cells is greater
Methods:
a)Set up replicate cell lines of non-metastatic spheroids under two media conditions: (i) high nutrient media and (ii)
low nutrient media.
b)Adhere spheroids to plates to enable motility to be expressed
© 2012 The Authors. Published by Blackwell Publishing Ltd10
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c)Transfer a subset of the population to new media (within the same media treatment conditions) periodically to main-
tain population growth. Continue for a number of generations, until a phenotypic difference between cell lines is
detected.
d)Measure difference in motility between cell lines, and compete evolved lines with ancestral lines under different nutri-
ent conditions to see whether evolved lines have a fitness advantage.
Predicted Results:
(A) (B)
A qualitative prediction showing: (a) cells which are evolved in a low-nutrient environment will become more motile than those
evolved in a high-nutrient environment over time, and (b) when evolved and ancestral cell lines are competed in high- and low-nutri-
ent conditions, the relative fitness (proportion of the evolved compared to the ancestral cells) of cell lines evolved in a low-nutrient
environment will be higher than those evolved in high nutrients as they are able to escape competition and access more resources than
those evolved in high nutrient. Under high-nutrient conditions, there is no benefit to dispersal and therefore cell lines are equally fit.
Literature Cited
Aktipis, C. A., C. C. Maley, and J. W. Pepper 2012. Dispersal Evolution
in Neoplasms: The Role of Disregulated Metabolism in the Evolution
of Cell Motility. Cancer Prevention Research 5(2):266–275.
Alizon, S., and P. Taylor 2008. Empty sites can promote altruistic behav-
ior. Evolution 62(6):1335–1344.
Anderson, A. R., A. M. Weaver, P. T. Cummings, and V. Quaranta 2006.
Tumor Morphology and Phenotypic Evolution Driven by Selective
Pressure from the Microenvironment. Cell 127(5):905–915.
Andersson, D. I. 2006. The biological cost of mutational antibiotic resis-
tance: any practical conclusions? Current Opinion in Microbiology 9
(5):461–465.
Andersson, D. I., and D. Hughes 2010. Antibiotic resistance and its cost:
is it possible to reverse resistance? Nature Reviews Microbiology 8
(4):260–271.
Araujo, R. P., and D. L. S. McElwain 2004. New insights into vascular
collapse and growth dynamics in solid tumors. Journal of Theoretical
Biology 228(3):335–346.
Attolini, C. S. O., and F. Michor 2009. Evolutionary Theory of Cancer.
Annals of the New York Academy of Sciences 1168(1):23–51.
Axelrod, R., D. E. Axelrod, and K. J. Pienta 2006. Evolution of coopera-
tion among tumor cells. Proceedings of the National Academy of Sci-
ences 103(36):13474–13479.
Banfield, W. G., P. A. Woke, C. M. MacKay, and H. L. Cooper 1965.
Mosquito Transmission of a Reticulum Cell Sarcoma of Hamsters. Sci-
ence 148(3674):1239–1240.
Barrick, J. E., D. S. Yu, S. H. Yoon, H. Jeong, T. K. Oh, D. Schneider, R.
E. Lenski et al. 2009. Genome evolution and adaptation in a long-term
experiment with Escherichia coli. Nature 461(7268):1243–1247.
Ben-Jacob, E., D. S. Coffey, and H. Levine 2012. Bacterial survival strate-
gies suggest rethinking cancer cooperativity. Trends in microbiology
20(9):403–410.
Bernards, R., and R. A. Weinberg 2002. Metastasis genes: A progression
puzzle. Nature 418(6900):823–823.
Bielas, J. H., K. R. Loeb, B. P. Rubin, L. D. True, and L. A. Loeb 2006.
From the Cover: Human cancers express a mutator phenotype. Pro-
ceedings of the National Academy of Sciences 103(48):18238–18242.
Blagosklonny, M. V. 2002. STI-571 must select for drug-resistant cells
but ‘no cell breathes fire out of its nostrils like a dragon’. Leukemia
16:570–572.
Blount, Z. D., C. Z. Borland, and R. E. Lenski 2008. Historical contin-
gency and the evolution of a key innovation in an experimental popu-
lation of Escherichia coli. Proceedings of the National Academy of
Sciences 105(23):7899–7906.
Bogdan, S., and C. Kl€ambt 2001. Epidermal growth factor receptor sig-
naling. Current Biology 11(8):R292–R295.
Boucher, Y., and R. K. Jain 1992. Microvascular Pressure Is the Principal
Driving Force for Interstitial Hypertension in Solid Tumors: Implica-
tions for Vascular Collapse. Cancer Research 52(18):5110–5114.
Bowler, D. E., and T. G. Benton 2005. Causes and consequences of ani-
mal dispersal strategies: relating individual behaviour to spatial
dynamics. Biological Reviews 80(02):205–225.
© 2012 The Authors. Published by Blackwell Publishing Ltd 11
Taylor et al. First steps in experimental cancer evolution
Brurberg, K. G., B. A. Graff, and E. K. Rofstad 2003. Temporal heteroge-
neity in oxygen tension in human melanoma xenografts. British Jour-
nal of Cancer 89(2):350–356.
Brurberg, K. G., H. K. Skogmo, B. A. Graff, D. R. Olsen, and E. K. Rofs-
tad 2005. Fluctuations in pO2 in poorly and well-oxygenated sponta-
neous canine tumors before and during fractionated radiation
therapy. Radiotherapy and Oncology 77(2):220–226.
Buckling, A., R. C. Maclean, M. A. Brockhurst, and N. Colegrave 2009.
The Beagle in a bottle. Nature 457(7231):824–829.
Bull, J. J., and W. R. Harcombe 2009. Population Dynamics Constrain
the Cooperative Evolution of Cross-Feeding. PLoS ONE 4(1):e4115.
Butler, L. M., D. B. Agus, H. I. Scher, B. Higgins, A. Rose, C. Cordon-
Cardo, H. T. Thaler et al. 2000. Suberoylanilide Hydroxamic Acid, an
Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate
Cancer Cells in Vitro and in Vivo. Cancer Research 60(18):5165–
5170.
Cairns, J. 1975. Mutation selection and the natural history of cancer.
Nature 255(5505):197–200.
Cardenas-Navia, L. I., D. Mace, R. A. Richardson, D. F. Wilson, S. Shan,
and M. W. Dewhirst 2008. The Pervasive Presence of Fluctuating Oxy-
genation in Tumors. Cancer Research 68(14):5812–5819.
Chao, L., and B. R. Levin 1981. Structured habitats and the evolution of
anticompetitor toxins in bacteria. Proceedings of the National Acad-
emy of Sciences 78(10):6324–6328.
Chen, J., K. Sprouffske, Q. Huang, and C. C. Maley 2011. Solving the
Puzzle of Metastasis: The Evolution of Cell Migration in Neoplasms.
PLoS ONE 6(4):e17933.
Comins, H. N., W. D. Hamilton, and R. M. May 1980. Evolutionarily
stable dispersal strategies. Journal of Theoretical Biology 82(2):205–
230.
Cooper, T. F., D. E. Rozen, and R. E. Lenski 2003. Parallel changes in
gene expression after 20,000 generations of evolution in Escherichia
coli. Proceedings of the National Academy of Sciences 100(3):1072–
1077.
Coussens, L. M., B. Fingleton, and L. M. Matrisian 2002. Matrix Metallo-
proteinase Inhibitors and Cancer—Trials and Tribulations. Science
295(5564):2387–2392.
Crespi, B., and K. Summers 2005. Evolutionary biology of cancer. Trends
in Ecology & Evolution 20(10):545–552.
Diaz Jr, L. A., R. T. Williams, J. Wu, I. Kinde, J. R. Hecht, J. Berlin, B.
Allen et al. 2012. The molecular evolution of acquired resistance to
targeted EGFR blockade in colorectal cancers. Nature 486(7404):537–
540.
Dingli, D., and M. A. Nowak 2006. Cancer biology: Infectious tumour
cells. Nature 443(7107):35–36.
Egeblad, M., and Z. Werb 2002. New functions for the matrix metallopro-
teinases in cancer progression. Nature Reviews Cancer 2(3):161–174.
Elena, S. F., and R. E. Lenski 2003. Evolution experiments with microor-
ganisms: the dynamics and genetic bases of adaptation. Nature
Reviews Genetics 4(6):457–469.
Fiegna, F., Y.-T. N. Yu, S. V. Kadam, and G. J. Velicer 2006. Evolution of
an obligate social cheater to a superior cooperator. Nature 441
(7094):310–314.
Frank, S. A. 2003. Repression of competition and the evolution of coop-
eration. Evolution 57(4):693–705.
Friedl, P., and K. Wolf 2003. Tumour-cell invasion and migration: diver-
sity and escape mechanisms. Nature Reviews Cancer 3(5):362–374.
Frumkin, D., A. Wasserstrom, S. Itzkovitz, T. Stern, A. Harmelin, R. Ei-
lam, G. Rechavi et al. 2008. Cell Lineage Analysis of a Mouse Tumor.
Cancer Research 68(14):5924–5931.
Gandon, S., and Y. Michalakis 1999. Evolutionarily Stable Dispersal Rate
in a Metapopulation with Extinctions and Kin Competition. Journal
of Theoretical Biology 199(3):275–290.
Gardner, A., and A. Grafen 2009. Capturing the superorganism: a formal
theory of group adaptation. Journal of Evolutionary Biology 22
(4):659–671.
Gerlinger, M., A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E.
Gronroos, P. Martinez et al. 2012. Intratumor Heterogeneity and
Branched Evolution Revealed by Multiregion Sequencing. New Eng-
land Journal of Medicine 366(10):883–892.
Gorre, M. E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. N.
Rao, and C. L. Sawyers 2001. Clinical Resistance to STI-571 Cancer
Therapy Caused by BCR-ABL Gene Mutation or Amplification. Sci-
ence 293(5531):876–880.
Greaves, M., and C. C. Maley 2012. Clonal evolution in cancer. Nature
481(7381):306–313.
Griffin, A. S., and S. A. West 2002. Kin selection: fact and fiction. Trends
in Ecology & Evolution 17(1):15–21.
Hamilton, W. D. 1964. The genetical evolution of social behaviour I &
II. Journal of Theoretical Biology 7:1–52.
Hamilton, W. D. 1996. Narrow roads of gene land. Vol 1. Evolution of
social behaviour. W. H. Freeman, Oxford.
Hamilton, W. D., and R. M. May 1977. Dispersal in stable habitats. Nat-
ure 269(5629):578–581.
Hanahan, D., and L. M. Coussens 2012. Accessories to the Crime: Func-
tions of Cells Recruited to the Tumor Microenvironment. Cancer Cell
21(3):309–322.
Hanahan, D., and R. A. Weinberg 2011. Hallmarks of Cancer: The Next
Generation. Cell 144(5):646–674.
Harris, A. L. 2002. Hypoxia - a key regulatory factor in tumour growth.
Nature Reviews Cancer 2(1):38–47.
Heckathorn, D. D. 1996. The Dynamics and Dilemmas of Collective
Action. American Sociological Review 61(2):250–277.
Hegreness, M., N. Shoresh, D. Damian, D. Hartl, and R. Kishony
2008. Accelerated evolution of resistance in multidrug environments.
Proceedings of the National Academy of Sciences 105(37):13977–
13981.
de Jong, J. S., P. J. van Diest, P. van der Valk, and J. P. A. Baak
1998. Expression of growth factors, growth-inhibiting factors, and
their receptors in invasive breast cancer. II: Correlations with
proliferation and angiogenesis. The Journal of Pathology 184(1):
53–57.
Kalas, W., J. L. Yu, C. Milsom, J. Rosenfeld, R. Benezra, P. Bornstein,
and J. Rak 2005. Oncogenes and Angiogenesis: Down-regulation of
Thrombospondin-1 in Normal Fibroblasts Exposed to Factors from
Cancer Cells Harboring Mutant Ras. Cancer Research 65(19):8878–
8886.
Klein, C. A. 2003. The Systemic Progression of Human Cancer: A Focus
on the Individual Disseminated Cancer Cell—The Unit of Selection.
Advances in Cancer Research, 89:35–67.
Kobayashi, S., T. J. Boggon, T. Dayaram, P. A. J€anne, O. Kocher, M.
Meyerson, B. E. Johnson et al. 2005. EGFR Mutation and Resistance
of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of
Medicine 352(8):786–792.
Komarova, N. L., and D. Wodarz. 2005. Drug resistance in cancer: Prin-
ciples of emergence and prevention. Proceedings of the National
Academy of Sciences 102(27):9714–9719.
K€ummerli, R., A. Gardner, S. A. West, and A. S. Griffin 2009. Limited
dispersal, budding dispersal, and cooperation: an experimental study.
Evolution 63(4):939–949.
© 2012 The Authors. Published by Blackwell Publishing Ltd12
First steps in experimental cancer evolution Taylor et al.
K€ummerli, R., P. van den Berg, A. S. Griffin, S. A. West, and A. Gardner
2010. Repression of competition favours cooperation: experimental
evidence from bacteria. Journal of Evolutionary Biology 23(4):699–
706.
Lee, V. T., and O. Schneewind 2001. Protein secretion and the pathogen-
esis of bacterial infections. Genes & Development 15(14):1725–1752.
Lehmann, L., and L. Keller 2006. The evolution of cooperation and altru-
ism – a general framework and a classification of models. Journal of
Evolutionary Biology 19(5):1365–1376.
Leigh, E. G. 1977. How does selection reconcile individual advantage
with the good of the group? Proceedings of the National Academy of
Sciences of the United States of America 74(10):4542–4546.
Lenski, R. E., and M. Travisano 1994. Dynamics of adaptation and diver-
sification: a 10,000-generation experiment with bacterial populations.
Proceedings of the National Academy of Sciences 91(15):6808–6814.
Lenski, R. E., M. R. Rose, S. C. Simpson, and S. C. Tadler 1991. Long-
Term Experimental Evolution in Escherichia coli. I. Adaptation and
Divergence During 2,000 Generations.. The American Naturalist 138
(6):1315–1341.
Leroi, A. M., V. Koufopanou, and A. Burt 2003. Cancer selection. Nature
Reviews Cancer 3(3):226–231.
Levin, B. R., V. Perrot, and N. Walker 2000. Compensatory Mutations,
Antibiotic Resistance and the Population Genetics of Adaptive Evolu-
tion in Bacteria. Genetics 154(3):985–997.
Liotta, L. A., and E. C. Kohn 2001. The microenvironment of the
tumour-host interface. Nature 411(6835):375–379.
Liotta, L. A., and E. C. Kohn 2003. Cancer’s deadly signature. Nature
Genetics 33(1):10–11.
Liotta, L. A., P. S. Steeg, and W. G. Stetler-Stevenson 1991. Cancer
metastasis and angiogenesis: An imbalance of positive and negative
regulation. Cell 64(2):327–336.
Loeb, L. A. 2001. A Mutator Phenotype in Cancer. Cancer Research 61
(8):3230–3239.
MacLean, R. C., A. R. Hall, G. G. Perron, and A. Buckling 2010. The
population genetics of antibiotic resistance: integrating molecular
mechanisms and treatment contexts. Nature Reviews Genetics 11
(6):405–414.
Maisnier-Patin, S., and D. I. Andersson 2004. Adaptation to the deleteri-
ous effects of antimicrobial drug resistance mutations by compensa-
tory evolution. Research in Microbiology 155(5):360–369.
Maynard Smith, J., and E. Szathmary 1995. The Major Transitions in
Evolution. Freeman, Oxford.
Merlo, L. M. F., J. W. Pepper, B. J. Reid, and C. C. Maley 2006. Cancer
as an evolutionary and ecological process. Nature Reviews Cancer 6
(12):924–935.
Michor, F., T. P. Hughes, Y. Iwasa, S. Branford, N. P. Shah, C. L. Saw-
yers, and M. A. Nowak 2005. Dynamics of chronic myeloid leukaemia.
Nature 435(7046):1267–1270.
Mueller, M. M., and N. E. Fusenig 2004. Friends or foes - bipolar effects
of the tumour stroma in cancer. Nature Reviews Cancer 4(11):839–
849.
Nadell, C. D., K. R. Foster, and J. B. Xavier 2010. Emergence of Spatial
Structure in Cell Groups and the Evolution of Cooperation. PLoS
Computational Biology 6(3):e1000716.
Novak, M., T. Pfeiffer, R. E. Lenski, U. Sauer, and S. Bonhoeffer 2006.
Experimental Tests for an Evolutionary Trade-Off between Growth
Rate and Yield in E. coli. The American Naturalist 168(2):242–251.
Nowell, P. C. 1976. The clonal evolution of tumor cell populations. Sci-
ence 194(4260):23–28.
Nunney, L 2003. The population genetics of multistage carcinogenesis.
Proceedings of the Royal Society of London. Series B: Biological Sci-
ences 270(1520):1183–1191.
Poon, A., B. H. Davis, and L. Chao 2005. The Coupon Collector and the
Suppressor Mutation. Genetics 170(3):1323–1332.
Queller, D. C. 1984. Kin selection and frequency dependence: a game
theoretic approach. Biological Journal of the Linnean Society 23 (2–
3):133–143.
Queller, D. C., E. Ponte, S. Bozzaro, and J. E. Strassmann 2003. Single-
Gene Greenbeard Effects in the Social Amoeba Dictyostelium discoid-
eum. Science 299(5603):105–106.
Rainey, P., and M. Travisano 1998. Adaptive radiation in a heteroge-
neous environment. Nature 394(6688):69–72.
Read, A. F., and S. Huijben 2009. PERSPECTIVE: Evolutionary biology
and the avoidance of antimicrobial resistance. Evolutionary Applica-
tions 2(1):40–51.
Ronce, O 2007. How Does It Feel to Be Like a Rolling Stone? Ten Ques-
tions About Dispersal Evolution. Annual Review of Ecology, Evolu-
tion, and Systematics 38(1):231–253.
Ross-Gillespie, A., A. Gardner, S. A. West, and A. S. Griffin 2007. Fre-
quency Dependence and Cooperation: Theory and a Test with Bacte-
ria. The American Naturalist 170(3):331–342.
Royuela, M., M. Ricote, M. S. Parsons, I. Garcıa-Tu~non, R. Paniagua,
and M. P. de Miguel 2004. Immunohistochemical analysis of the IL-6
family of cytokines and their receptors in benign, hyperplasic, and
malignant human prostate. The Journal of Pathology 202(1):41–49.
Schrag, S. J., V. Perrot, and B. R. Levin 1997. Adaptation to the fitness
costs of antibiotic resistance in Escherichia coli. Proceedings of the
Royal Society of London. Series B: Biological Sciences 264(1386):1287
–1291.
Sequist, L. V., B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B.
Turke, P. Fidias, K. Bergethon et al. 2011. Genotypic and Histological
Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.
Science Translational Medicine 3(75):75ra26.
Shah, N. P., B. J. Skaggs, S. Branford, T. P. Hughes, J. M. Nicoll, R. L. Pa-
quette, and C. L. Sawyers. 2007. Sequential ABL kinase inhibitor ther-
apy selects for compound drug-resistant BCR-ABL mutations with
altered oncogenic potency. The Journal of Clinical Investigation 117
(9):2562–2569.
Shannon, K. M. 2002. Resistance in the land of molecular cancer thera-
peutics. Cancer Cell 2(2):99–102.
Sniegowski, P. D., P. J. Gerrish, and R. E. Lenski 1997. Evolution of high
mutation rates in experimental populations of E. coli. Nature 387
(6634):703–705.
Stetler-Stevenson, W. G., S. Aznavoorian, and L. A. Liotta 1993. Tumor
Cell Interactions with the Extracellular Matrix During Invasion and
Metastasis. Annual Review of Cell Biology 9(1):541–573.
Stoecklein, N. H., S. B. Hosch, M. Bezler, F. Stern, C. H. Hartmann, C.
Vay, A. Siegmund et al. 2008. Direct Genetic Analysis of Single Dis-
seminated Cancer Cells for Prediction of Outcome and Therapy Selec-
tion in Esophageal Cancer. Cancer Cell 13(5):441–453.
Strassman, J. E., Y. Zhu, and D. C. Queller 2000. Altruism and social
cheating in the social amoeba Dictyostelium discoideum. Nature 408
(6815):965.
Szakacs, G., J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M.
Gottesman 2006. Targeting multidrug resistance in cancer. Nature
Reviews Drug Discovery 5(3):219–234.
Taylor, P 1992. Altruism in viscous populations— an inclusive fitness
model. Evolutionary Ecology 6(4):352–356.
© 2012 The Authors. Published by Blackwell Publishing Ltd 13
Taylor et al. First steps in experimental cancer evolution
Taylor, T. B., and A. Buckling 2010. Competition and Dispersal in Pseu-
domonas aeruginosa. The American Naturalist 176(1):83–89.
Taylor, P. D., and S. A. Frank 1996. How to Make a Kin Selection Model.
Journal of Theoretical Biology 180(1):27–37.
Tlsty, T. D. 2001. Stromal cells can contribute oncogenic signals. Semi-
nars in Cancer Biology 11(2):97–104.
Turke, A. B., K. Zejnullahu, Y. Wu, Y. Song, D. Dias-Santagata, E. Lifsh-
its, L. Toschi et al. 2010. Preexistence and Clonal Selection of MET
Amplification in EGFR Mutant NSCLC. Cancer Cell 17(1):77–88.
Turner, P. E., and L. Chao 1999. Prisoner’s dilemma in an RNA virus.
Nature 398(6726):441–443.
Vaupel, P., and L. Harrison 2004. Tumor Hypoxia: Causative Factors,
Compensatory Mechanisms, and Cellular Response. The Oncologist 9
(suppl 5):4–9.
Velicer, G. J., L. Kroos, and R. E. Lenski 2000. Developmental cheating in
the social bacteriumMyxococcus xanthus. Nature 404(6778):598–601.
Vogelstein, B., and K. W. Kinzler 1993. The multistep nature of cancer.
Trends in Genetics 9(4):138–141.
Weaver, V. M., and P. Gilbert 2004. Watch thy neighbor: cancer is a
communal affair. Journal of Cell Science 117(8):1287–1290.
Wei, Y., X. Wang, J. Liu, I. Nememan, A. H. Singh, H. Weiss, and B.
R. Levin 2011. The population dynamics of bacteria in physically
structured habitats and the adaptive virtue of random motility.
Proceedings of the National Academy of Sciences 108(10):4047–
4052.
West, S. A., S. P. Diggle, A. Buckling, A. Gardner, and A. S. Griffin 2007.
The Social Lives of Microbes. Annual Review of Ecology, Evolution,
and Systematics 38(1):53–77.
Wielgoss, S., J. E. Barrick, O. Tenaillon, S. Cruveiller, B. Chane-Woon-
Ming, C. Medigue, R. E. Lenski et al. 2011. Mutation Rate Inferred
From Synonymous Substitutions in a Long-Term Evolution Experi-
ment With Escherichia coli. G3: Genes, Genomes, Genetics 1(3):183–
186.
Woods, R., D. Schneider, C. L. Winkworth, M. A. Riley, and R. E. Lenski
2006. Tests of parallel molecular evolution in a long-term experiment
with Escherichia coli. Proceedings of the National Academy of Sci-
ences 103(24):9107–9112.
Yap, T., C. Swanton, and J. de Bono 2012. Personalization of prostate
cancer prevention and therapy: are clinically qualified biomarkers in
the horizon? The EPMA Journal 3(1):1–7.
Zhang, L., W. Zhou, V. E. Velculescu, S. E. Kern, R. H. Hruban, S. R.
Hamilton, B. Vogelstein et al. 1997. Gene expression profiles in nor-
mal and cancer cells. Science, 276(5316):1268–1272.
© 2012 The Authors. Published by Blackwell Publishing Ltd14
First steps in experimental cancer evolution Taylor et al.
